Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 dose escalating study to determine incidence of dose limiting toxicities of single agent ATX-101 given by intravenous infusion every week in patients with advanced solid tumours

Next Previous
X
Search
Trial Profile

A phase 1 dose escalating study to determine incidence of dose limiting toxicities of single agent ATX-101 given by intravenous infusion every week in patients with advanced solid tumours

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATX 101 (Primary) ; Dexamethasone; Famotidine; Paracetamol; Promethazine; Ranitidine
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Therapim

    • Most Recent Events

    • 01 Feb 2023 Results(n=25) assessing safety of ATX-101 in patients with advanced solid tumours published in the Oncogene.
    • 09 Nov 2022 Status changed from recruiting to completed, according to a Nordic Nanovector media release.
    • 08 Jun 2021 Results (data cut off Jan 2021, n=22) presented at the 57th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top